Description
Although various non-pharmaceutical strategies addressed to the primary prevention of cardiovascular diseases such as tobacco control policies, reducing the consumption of harmful food, and increasing physical activity still represent a key strategy, often they are not sufficient. Moreover, despite the availability of a plethora of pharmaceutic approaches specifically targeting mechanisms involved in cardiovascular diseases over recent years, the burden of these pathologies has only been marginally alleviated. Therefore, new pharmaceutical and non-pharmaceutical strategies are necessary for both primary and secondary prevention to reduce the burden of cardiovascular diseases. The present reprint brings together original and review articles aiming to highlight the advances in the development of modern pharmaceutics for cardiovascular diseases in recent years.
